• No other company develops a DNA (or a biological agent) based on p62. We were the first, and due to IP protection will remain to be the only anti-cancer p62 biologics.

  • Elenagen does not compete with any other anti-cancer product and/or treatment modality. In contrast, Elenagen will be used in combination with other anti-cancer standards of care (e.g. chemotherapy, radiotherapy, immunotherapies).

Elenagen does not have potential competitors, only potential synergetic partners.